% | $
Quotes you view appear here for quick access.

Endocyte, Inc. (ECYT) Message Board

sunshinecamesoftly2002 3 posts  |  Last Activity: Apr 16, 2015 7:57 PM Member since: Sep 22, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • sunshinecamesoftly2002 sunshinecamesoftly2002 Apr 16, 2015 7:57 PM Flag

    The number of patients in each cohort is very low I believe only 4 per cohort and many are not FR positive. It is possible once they start the phase 1b portion of the 1456 trial they may pick up speed but that would require recruitment of many more sites. Ron Ellis has mentioned in prior biotech meetings he expected to quickly recruit for the phase 1b trial and I hope he follows through. With all the new oncology platforms in development, especially in immunotherapy, the SOC is in flux for many of the indications they hope to find success. Time is of the essence

  • I have been disappointed in the slow movement forward on the phase 1 trials using the tubulysin drug with about 20 patients enrolled in over a 6 month time frame. Now seeing the further development of ECYT technology may explain this as they have more potent/effective drugs now in development using antifolate ligands and perhaps multiple drug payloads.
    as per their recent press release for AACR
    High affinity antifolates can be used in an SMDC format serving as both a high affinity targeting ligand and as a second drug having different, and perhaps a complementary mechanism of action to yield greater antitumor activity.

  • Reply to

    Endocyte Turn on a Dime

    by dkenigsberg Apr 9, 2015 12:23 AM
    sunshinecamesoftly2002 sunshinecamesoftly2002 Apr 15, 2015 8:53 AM Flag

    I am expecting to see some complete or partial responses with the 4th and 5th cohorts. I am surprised at their slow enrollment of patients in this phase 1 study but hope the trial speeds up from here

5.79-0.20(-3.34%)11:18 AMEDT